Literature DB >> 20105138

Immunoglobulin IgG Fc-receptor polymorphisms and HLA class II molecules in Guillain-Barré syndrome.

S Sinha1, K N Prasad, D Jain, K K Nyati, S Pradhan, S Agrawal.   

Abstract

OBJECTIVE: To analyze host genetic factors immunoglobulin G Fc receptors (FcgammaRs) and human leukocyte antigen (HLA) class II in GBS patients.
METHODS: FcgammaRIIA, IIIA and IIIB polymorphisms were studied in 80 each GBS patients and healthy controls by allele specific PCR. HLA class II DRbeta1 and DQbeta1 typing was performed at the two-digit level by PCR in randomly selected 54 GBS patients and 202 controls.
RESULTS: FcgammaRIIA-H/H (56% vs 9%; P < 0.0001) and FcgammaRIIIA-V/V (40% vs 13%; P < 0.0001) genotypes, H131 allele frequencies (0.73 vs 0.26, P < 0.0001) and HLA DQbeta1*060x (OR, 1.96; 95% CI, 1.26-3.04; P < 0.01) were significantly increased in GBS than controls. DRbeta1*0701 alone (OR, 10; 95% CI, 45.90-2.25; P < 0.001) and together with FcgammaRIIA-H/H (OR, 11.03; 95% CI, 2.63-46.20; P < 0.001) was significantly associated with GBS patients having microbiological evidence of recent infection.
CONCLUSIONS: The study indicates that homozygous FcgammaRIIA and FcgammaRIIIA genotypes and FcgammaRIIA H131 allele are associated with GBS. HLA class II molecule DRbeta1*0701 is identified as novel genetic risk factor for development of GBS in patients with preceding infection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20105138     DOI: 10.1111/j.1600-0404.2009.01229.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  15 in total

1.  Association of CD1 and FcγR gene polymorphisms with Guillain-Barré syndrome susceptibility: a meta-analysis.

Authors:  Liang Zhang; Lijun Liu; Hong Li; Lei Guo; Qing Yu; Jijun Teng
Journal:  Neurol Sci       Date:  2018-09-19       Impact factor: 3.307

Review 2.  A review of the role of genetic factors in Guillain-Barré syndrome.

Authors:  Amin Safa; Tahereh Azimi; Arezou Sayad; Mohammad Taheri; Soudeh Ghafouri-Fard
Journal:  J Mol Neurosci       Date:  2020-10-07       Impact factor: 3.444

3.  Tumor necrosis factor alpha 308 G/A polymorphism and Guillain-Barré syndrome risk.

Authors:  Hong Jiao; Weizhi Wang; Huabing Wang; Yun Wu; Lihua Wang
Journal:  Mol Biol Rep       Date:  2011-05-22       Impact factor: 2.316

4.  Guillain-Barré syndrome and glioblastoma.

Authors:  Isaac Melguizo; Mark Gilbert; Sudhakar Tummala
Journal:  J Neurooncol       Date:  2010-11-23       Impact factor: 4.130

Review 5.  Guillain-Barré syndrome, transverse myelitis and infectious diseases.

Authors:  Yhojan Rodríguez; Manuel Rojas; Yovana Pacheco; Yeny Acosta-Ampudia; Carolina Ramírez-Santana; Diana M Monsalve; M Eric Gershwin; Juan-Manuel Anaya
Journal:  Cell Mol Immunol       Date:  2018-01-29       Impact factor: 11.530

Review 6.  Human Leukocyte Antigen DQB1 (HLA-DQB1) Polymorphisms and the Risk for Guillain-Barré Syndrome: A Systematic Review and Meta-Analysis.

Authors:  Peng-Peng Jin; Li-Li Sun; Bo-Jun Ding; Na Qin; Bin Zhou; Feng Xia; Li Li; Li-Juan Liu; Xue-Dong Liu; Gang Zhao; Wen Wang; Yan-Chun Deng; Shuang-Xing Hou
Journal:  PLoS One       Date:  2015-07-23       Impact factor: 3.240

Review 7.  Role of Campylobacter jejuni infection in the pathogenesis of Guillain-Barré syndrome: an update.

Authors:  Kishan Kumar Nyati; Roopanshi Nyati
Journal:  Biomed Res Int       Date:  2013-08-13       Impact factor: 3.411

Review 8.  Role of cytokines and Toll-like receptors in the immunopathogenesis of Guillain-Barré syndrome.

Authors:  Kishan Kumar Nyati; Kashi Nath Prasad
Journal:  Mediators Inflamm       Date:  2014-09-22       Impact factor: 4.711

9.  Young woman with Guillain-Barré syndrome and cervical transverse myelitis-A new GBS variant, not coincidence.

Authors:  Jenna Gharzeddine; Brian Renner; Natalie Wassall; Kristen Tran; Antonio Liu
Journal:  Clin Case Rep       Date:  2020-04-21

Review 10.  Biomarkers of Guillain-Barré Syndrome: Some Recent Progress, More Still to Be Explored.

Authors:  Ying Wang; Shuang Sun; Jie Zhu; Li Cui; Hong-Liang Zhang
Journal:  Mediators Inflamm       Date:  2015-09-16       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.